259 related articles for article (PubMed ID: 11205906)
1. Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.
Goel A; Augustine S; Baranowska-Kortylewicz J; Colcher D; Booth BJ; Pavlinkova G; Tempero M; Batra SK
Clin Cancer Res; 2001 Jan; 7(1):175-84. PubMed ID: 11205906
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
3. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
[TBL] [Abstract][Full Text] [Related]
4. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
5. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.
Goel A; Colcher D; Baranowska-Kortylewicz J; Augustine S; Booth BJ; Pavlinkova G; Batra SK
Cancer Res; 2000 Dec; 60(24):6964-71. PubMed ID: 11156397
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy of human colon cancer xenografts by using 131I labeled-CAb1 F(ab')2.
Li L; Xu HY; Mi L; Bian HJ; Qin J; Xiong H; Feng Q; Wen N; Tian R; Xu LQ; Shen XM; Tang H; Chen ZN
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1238-44. PubMed ID: 16979831
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
[TBL] [Abstract][Full Text] [Related]
8. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.
Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK
Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
[TBL] [Abstract][Full Text] [Related]
10. Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
Greiner JW; Ullmann CD; Nieroda C; Qi CF; Eggensperger D; Shimada S; Steinberg SM; Schlom J
Cancer Res; 1993 Feb; 53(3):600-8. PubMed ID: 8425194
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
12. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).
Tschmelitsch J; Barendswaard E; Williams C; Yao TJ; Cohen AM; Old LJ; Welt S
Cancer Res; 1997 Jun; 57(11):2181-6. PubMed ID: 9187118
[TBL] [Abstract][Full Text] [Related]
14. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.
Colapinto EV; Zalutsky MR; Archer GE; Noska MA; Friedman HS; Carrel S; Bigner DD
Cancer Res; 1990 Mar; 50(6):1822-7. PubMed ID: 2407345
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates.
Schlom J; Eggensperger D; Colcher D; Molinolo A; Houchens D; Miller LS; Hinkle G; Siler K
Cancer Res; 1992 Mar; 52(5):1067-72. PubMed ID: 1310638
[TBL] [Abstract][Full Text] [Related]
18. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
Lee Y; Bullard DE; Humphrey PA; Colapinto EV; Friedman HS; Zalutsky MR; Coleman RE; Bigner DD
Cancer Res; 1988 May; 48(10):2904-10. PubMed ID: 2452014
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1).
Siler K; Eggensperger D; Hand PH; Milenic DE; Miller LS; Houchens DP; Hinkle G; Schlom J
Biotechnol Ther; 1993; 4(3-4):163-81. PubMed ID: 8292968
[TBL] [Abstract][Full Text] [Related]
20. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
